Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Gastrointestinal Stromal Tumors 12Leukemia, Myeloid, Chronic-Phase 9Leukemia 7Leukemia, Myeloid, Acute 6Blast Crisis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Leukemia, Myeloid, Accelerated Phase 5Gliosarcoma 5Glioblastoma 5Brain Neoplasms 5Glioma 4Unspecified Adult Solid Tumor, Protocol Specific 3Prostatic Neoplasms 3Philadelphia Chromosome 3Pancreatic Neoplasms 3Oligodendroglioma 3Myeloproliferative Disorders 3Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Central Nervous System Neoplasms 3Astrocytoma 3Primary Myelofibrosis 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2

Interventions

NVP-BKM120 1Imatinib Mesylate 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × 3rd Line GIST × Imatinib Mesylate × Clear all
NCT01468688 2020-12-21

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

Novartis

Phase 1 Completed
60 enrolled
Sarcoma

3rd Line GIST

Data powered by HemOnc (CC BY 4.0) Colophon âš¡